NCT07201545View on ClinicalTrials.gov

Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

November 26, 2025

Study Completion Date

November 26, 2025

Conditions
Healthy Subjects
Interventions
DRUG

Bempedoic acid

"180 mg film coated tablet administered as FDC or co-administered with ezetimibe~Component of FDC"

DRUG

Ezetimibe

"10 mg tablet administered as FDC or co-administered with bempedoic acid~Component of FDC"

DRUG

Rosuvastatin

"20 mg film coated tablet administered individually or as FDC~Component of FDC"

Trial Locations (1)

4250-449

Research Site, Porto

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY